Predictability of buprenorphine-naloxone treatment retention

Stanford University et al found that US patients with opioid use disorder/dependence treated with buprenorphine-naloxone prescriptions have high (∼60%) treatment attrition by 6 months. Machine learning models trained on diverse electronic health record datasets appear to predict this as accurately as clinical experts.